Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03131687 · ClinicalTrials.gov registry record · Phase 2
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 318
- Enrollment target
NCT03131687: Completed Phase 2 study, sponsored by Eli Lilly and Company.
NCT03131687 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 318 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (139% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03131687, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 318 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of the study drug tirzepatide in participants with type 2 diabetes mellitus.
Primary Outcome
HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.This was a Bayesian dose response analysis of HbA1c (%) change from baseline. At baseline: Mean (SD = Standard Deviation) of baseline HbA1c (%). After baseline: Posterior Mean (SD = Posterior Standard Deviation) of HbA1c (%) change from baseline. The Least Squares Mean is Posterior mean.
Interventions
- DRUG Placebo
- DRUG tirzepatide
- DRUG Dulaglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 318 participants |
| Start Date | 2017-05-24 |
| Est. Completion | 2018-08-01 |
| Phase | Phase 2 |
What the finished NCT03131687 record still lists
NCT03131687 is an interventional study that assigns participants to a tested intervention. The registered 318 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (139% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03131687 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03131687 about?
NCT03131687 is a clinical study titled "A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus". The purpose of this study is to evaluate the efficacy of the study drug tirzepatide in participants with type 2 diabetes mellitus.
What is the current status of trial NCT03131687?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 318 participants. The study started on 2017-05-24. Estimated completion is 2018-08-01.
What interventions are being tested in trial NCT03131687?
The interventions under investigation include: Placebo (DRUG), tirzepatide (DRUG), Dulaglutide (DRUG).
Who is sponsoring clinical trial NCT03131687?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03131687's enrollment target sits among peer trials
318 153rd of 2000 higher than 1,846 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05488340 · 318 participants · Phase 2
A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)
- NCT05675735 · 318 participants · NA
Leveraging Regulatory Flexibility for Methadone Take-Home Dosing to Improve Retention in Treatment for Opioid Use Disorder
- NCT05895786 · 318 participants · Phase 3
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
- NCT06051617 · 318 participants · Phase 3
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI